Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Lucid Diagnostics stock

Learn how to easily invest in Lucid Diagnostics stock.

Lucid Diagnostics Inc is a medical devices business based in the US. Lucid Diagnostics shares (LUCD) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Lucid Diagnostics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LUCD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Lucid Diagnostics stock price (NASDAQ: LUCD)

Use our graph to track the performance of LUCD stocks over time.

Lucid Diagnostics shares at a glance

Information last updated 2022-07-06.
Latest market close$2.53
52-week range$1.69 - $13.52
50-day moving average $2.08
200-day moving average $4.52
Wall St. target price$8.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.54

Buy Lucid Diagnostics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lucid Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lucid Diagnostics price performance over time

Historical closes compared with the close of $2.53 from 2022-07-06

1 week (2022-06-30) 11.95%
1 month (2022-06-07) 27.78%
3 months (2022-04-07) -15.38%
6 months (2022-01-07) -44.03%
1 year (2021-07-03) N/A
2 years (2020-07-03) N/A
3 years (2019-07-03) N/A
5 years (2017-07-03) N/A

Lucid Diagnostics financials

Revenue TTM $689,000
Gross profit TTM $-85,000
Return on assets TTM -69.9%
Return on equity TTM -243.62%
Profit margin 0%
Book value $1.32
Market capitalisation $92.7 million

TTM: trailing 12 months

Lucid Diagnostics share dividends

We're not expecting Lucid Diagnostics to pay a dividend over the next 12 months.

You may also wish to consider:

Lucid Diagnostics overview

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Frequently asked questions

What percentage of Lucid Diagnostics is owned by insiders or institutions?
Currently 78.375% of Lucid Diagnostics shares are held by insiders and 7.122% by institutions.
When does the fiscal year end for Lucid Diagnostics?
Lucid Diagnostics's fiscal year ends in December.
Where is Lucid Diagnostics based?
Lucid Diagnostics's address is: One Grand Central Place, New York, NY, United States, 10165
What is Lucid Diagnostics's ISIN number?
Lucid Diagnostics's international securities identification number is: US54948X1090

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site